Adjuvant endocrine therapy for operable breast cancer

Area of Science:

• Oncology
• Endocrinology
• Clinical Trials

Background:

• Adjuvant endocrine therapy for operable breast cancer has a long history, with acceptance growing in recent decades.
• Early trials showed limited survival benefits, potentially due to concurrent hormone therapy for metastases.
• Renewed interest emerged with positive results from ovarian ablation trials and the success of tamoxifen in post-menopausal women.

Purpose of the Study:

• To review the historical development and current understanding of adjuvant endocrine therapy for operable breast cancer.
• To analyze the impact of different tamoxifen dosing schedules on trial outcomes.
• To evaluate the efficacy of adjuvant tamoxifen in pre- and post-menopausal patients, including its relationship with estrogen receptor status.

Main Methods:

• Review of historical data and randomized controlled trials on adjuvant endocrine therapy for breast cancer.
• Combined analysis of results from multiple large tamoxifen trials.
• Examination of data from the Scottish and NATO trials regarding tamoxifen efficacy and duration.

Main Results:

• Combined analysis suggests CMF (cyclophosphamide, methotrexate, and fluorouracil) as the preferred adjuvant therapy for pre-menopausal patients, possibly via ovarian effects.
• Adjuvant tamoxifen demonstrated an overall survival advantage in both pre- and post-menopausal patients in the Scottish and NATO trials, independent of estrogen receptor (ER) status.
• The optimal duration of tamoxifen therapy (2 vs. 3 years) remains uncertain.

Conclusions:

• Adjuvant tamoxifen provides a survival advantage for operable breast cancer patients, including pre-menopausal women.
• Estrogen receptor status does not appear to influence the benefit of adjuvant tamoxifen.
• Further investigation is needed regarding the potential role of post-relapse tamoxifen therapy.